---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-251966"
form_type: "8-K"
ticker: null
cik: "0001780097"
company_name: "Baudax Bio, Inc."
filed_at: "2023-10-06T23:59:59+00:00"
generated_at: "2026-06-10T03:33:27.312518+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Baudax Bio Corporate Controller resigns; appoints Interim CFO via Danforth

## Summary
- Jillian Dilmore resigns as Corporate Controller, PFO, PAO, and Corporate Secretary effective Oct 9, 2023; she will provide continued consulting support.
- Board appoints Natalie McAndrew as Interim CFO effective Oct 9, 2023; she will also serve as PFO and PAO through Danforth Advisors.
- McAndrew, age 49, is a Director at Danforth Advisors, a life science advisory firm; no family relationships with executives.

## SEC filing metadata
- accession: 0001193125-23-251966
- form_type: 8-K
- cik: 0001780097
- company_name: Baudax Bio, Inc.
- filed_at: 2023-10-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1780097/000119312523251966/0001193125-23-251966-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1780097/000119312523251966/d416304d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-251966
- JSON: https://secwatch.observer/filing/0001193125-23-251966.json
- Plain text: https://secwatch.observer/filing/0001193125-23-251966.txt

## Key facts
- Executive change
  Jillian Dilmore resigned as Corporate Controller, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary at Baudax Bio, Inc..
  - Action: resigned
  - Role: Corporate Controller, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary
  source text: On October 2, 2023, Jillian Dilmore, the Corporate Controller, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary of Baudax Bio, Inc. (the “Company”) notified the Company of her decision to resign effective as of October 9, 2023 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1780097/000119312523251966/0001193125-23-251966-index.htm
- Executive change
  Natalie McAndrew was appointed as Interim Chief Financial Officer at Baudax Bio, Inc..
  - Action: appointed
  - Role: Interim Chief Financial Officer
  source text: On October 5, 2023, the board of directors of the Company appointed Natalie McAndrew as Interim Chief Financial Officer, effective as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1780097/000119312523251966/0001193125-23-251966-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.